Polidocanol Sclerotherapy of Pharynges for Obstructive Sleep Apnea (OSA) and Snoring Subjects(SS)

Preliminary Study on Submucous Sclerosis of Pharynges With 1% Polidocanol to Treat Obstructive Sleep Apnea (OSA) & Snoring Subjects (SS)

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00399451

Enrollment

Registered

2006-11-14

Start date

2006-12-31

Completion date

2009-06-30

Last updated

2006-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apnea, Snoring

Keywords

Sleep Apnea,Obstructive, apnea-hypopnea index (AHI), polidocanol, sclerotherapy, pharynges

Brief summary

The aim of this prospective study is to evaluate the results of polidocanol sclerotherapy of pharynx for OSAS & SS,to reduce pharyngeal compliance.

Detailed description

Polidocanol submucous sclerosis in the part of pharynges with 1% polidocanol injection.The injection should be in the retropharyngeal submucosa and lateral pharyngeal bands and lateral pharyngeal submucosa and in front submucosa of soft palate.The injection is multi-point,and each point injection is 0.3\ 0.5ml;the total quantity/each time is not more than 5ml.Every patient have to be treated about 1\ 2 time.

Interventions

DRUGPolidocanol Sclerotherapy

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* OSAS & SS which palatopharyngeal collapse.

Exclusion criteria

* obstructive sleep apnea syndrome (osas) & snoring subjects (ss),which anatomic narrow result in.

Design outcomes

Primary

Measure	Time frame
apnea-hypopnea index (AHI)is on polysomnography(PSG),to compare AHIanterior and posterior treatment.	—

Secondary

Measure	Time frame
Arterial oxygen saturation (SaO2) and body mass index (BMI)will be measured on polysomnography	—

Contacts

Primary ContactHongyan Chen, MB

lychy2006@yahoo.com.cn+86-0419-3221423

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026